Physician profile
Tara Gustilo
NPI 1710913900
$721.23
in general payments reported to CMS, 2019-2025
18 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.68 · 2023: $104 · 2024: $239 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $163.07 | 2022-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $93.03 | 2024-2025 | Ultomiris |
| Ucb, INC. | $76.34 | 2024-2025 | Rystiggo, Briviact |
| Ardelyx, INC. | $66.12 | 2024-2025 | Ibsrela |
| Argenx US, INC. | $50.09 | 2024-2025 | Vyvgart |
| Exeltis, USA INC. | $27.36 | 2023 | Slynd |
| Tg Therapeutics, INC. | $25.57 | 2025 | |
| Lundbeck LLC | $24.66 | 2025 | Vyepti |
| Redhill Biopharma INC. | $24.35 | 2025 | Talicia |
| Merz Pharmaceuticals, LLC | $23.82 | 2025 | Inbrija, Xeomin |
| Astellas Pharma US INC | $22.24 | 2023 | Veozah |
| Neurocrine Biosciences, INC. | $21.88 | 2025 | |
| Dexcom, INC. | $20.04 | 2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $19.84 | 2025 | Ocrevus Zunovo |
| Idorsia Pharmaceuticals US INC | $17.15 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $16.75 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $15.09 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Gustilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.